Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2022-09-09 00:00:00 ET · period of report 2022-09-07 · accession 0001567619-22-017237 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-09-09 | 2022-06-23 | ARQT | Watanabe Todd Franklin | Pres, CEO, Dir | G - Gift | $0.00 | -269.0K | 382.9K | -41% | $0 | |
| 2022-09-09 | 2022-09-07 | ARQT | Watanabe Todd Franklin | Pres, CEO, Dir | S - Sale | $21.51 | -1,000 | 381.9K | -0.3% | -$21.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-06-23 | G | D | 268,964 | $0.00 | 382,907 | D | — | — | (F1) Includes 109,925 restricted stock units. |
| 2 | Common | Common Stock | 2022-09-07 | S | D | 1,000 | $21.51 | 381,907 | D | — | — | (F1) Includes 109,925 restricted stock units. |